NeoGraph Analytics
Medical DevicesNorth America2023 – 2032

Global Continuous Glucose Monitoring Market Size, Share and Trends Analysis

Global CGM market valued at US$9.8 Bn (2023), projected to reach US$36.7 Bn by 2032 at 15.8% CAGR.

Revenue, 2023

$9.8B

Forecast, 2032

$36.7B

CAGR, 2024-2032

15.8%

Report Coverage

North America

Code: continuous-glucose-monitoring-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The global continuous glucose monitoring market was valued at US$9.8 Bn in 2023 and is projected to reach US$36.7 Bn by 2032, growing at a 15.8% CAGR. North America dominates with 42% share. Dexcom and Abbott lead the competitive landscape. Real-time CGM holds 62% product share while flash monitoring is the fastest-growing segment. Expansion into consumer wellness and APAC markets presents significant growth opportunities.

02

Key Highlights

1

North America leads with 42% share driven by high diabetes prevalence and favorable reimbursement policies.

2

Real-time CGM dominates with 62% product share; flash monitoring is the fastest-growing segment.

3

Dexcom and Abbott together command over 60% of the global CGM market revenue.

03

Market Overview

Market Context

The global CGM market is driven by rising diabetes prevalence, technological advancements in sensor accuracy, and expanding insurance coverage. Real-time CGM leads adoption, while flash monitoring gains traction in cost-sensitive markets. Integration with insulin pumps and digital health platforms accelerates growth.

The global CGM market is experiencing high growth driven by rising diabetes prevalence, sensor technology advancements, and expanding reimbursement coverage. Real-time CGM leads adoption while flash monitoring gains share in cost-sensitive regions. Integration with closed-loop insulin delivery and digital health platforms further accelerates market expansion.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Integration of CGM with closed-loop insulin delivery systemsExpansion into non-diabetes consumer wellness marketAI-powered predictive analytics for glucose managementDevelopment of implantable and needle-free CGM sensors
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 15.8%

Base Year (2023)

$9.8B

Forecast (2032)

$36.7B

CAGR (2024-2032)

15.8%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$9.80B
2024$11.35B
2025$13.14B
2026$15.22B
2027$17.62B
2028$20.41B
2029$23.63B
2030$27.36B
2031$31.69B
2032$36.69B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The CGM market will grow from US$9.8 Bn in 2023 to US$36.7 Bn by 2032 at a 15.8% CAGR. Growth is fueled by expanding diabetic populations, AI-driven analytics, and consumer wellness adoption. Asia Pacific will outpace other regions, while real-time CGM maintains dominance.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America42.0%14.2%United States
Europe29.0%16.5%Germany
Asia Pacific29.0%18.8%China

North America

#1
Share: 42.0%CAGR: 14.2%

Largest market: United States

Europe

#2
Share: 29.0%CAGR: 16.5%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising global diabetes prevalence and incidence rates
  • Technological advances improving sensor accuracy and wearability
  • Expanding insurance and reimbursement coverage globally
06

Market Segmentation

By End User
Market share distribution across 3 segments
By End User — market share by segment, in percent.
SegmentShare
HospitalsLargest end-user segment driven by inpatient monitoring and critical care applications.40.0%
Home Care SettingsFast-growing segment as patients increasingly prefer remote self-monitoring solutions.35.0%
Clinics & Diagnostic CentersAdopts CGM for outpatient diabetes management and diagnostic screening programs.25.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Product Type
Market share distribution across 2 segments
By Product Type — market share by segment, in percent.
SegmentShare
Real-Time CGM (RT-CGM)Provides continuous real-time glucose readings transmitted to a receiver or smartphone; leads the market with broad clinical adoption.62.0%
Flash Glucose Monitoring (FGM)Requires user-initiated scanning for glucose data; growing in cost-sensitive markets due to lower price points.38.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User List

  • Hospitals
  • Home Care Settings
  • Clinics & Diagnostic Centers
07

Regional Analysis

1

North America

Lead: United States
CAGR: 14.2%Share: 42.0%

Largest market driven by high diabetes prevalence, favorable reimbursement, and presence of Dexcom and Abbott headquarters.

2

Europe

Lead: Germany
CAGR: 16.5%Share: 29.0%

Growing rapidly due to EU MDR compliance improvements, rising type 2 diabetes cases, and expanding NHS coverage in the UK.

3

Asia Pacific

Lead: China
CAGR: 18.8%Share: 29.0%

Fastest-growing region fueled by massive diabetic population, increasing healthcare spending, and growing awareness of CGM technology.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
38.0%
+13.5%
Germany
8.0%
+15.2%
China
12.0%
+22.4%
08

Competitive Landscape

D

Dexcom, Inc.

United States

Leader4.1B

Dominates standalone CGM revenue with the G7 system, covered by all major U.S. PBMs and reaching over 6 million eligible patients globally.

U.S.-based market leader in standalone CGM systems known for the G7 real-time platform with 15-day sensor wear and broad PBM coverage.

A

Abbott Laboratories

United States

Challenger3.2B

Second-largest globally with the FreeStyle Libre franchise targeting US$10 Bn in franchise sales by 2028; launched consumer Lingo CGM in 2024.

Global healthcare giant and #2 CGM provider with the FreeStyle Libre franchise targeting US$10 Bn in franchise sales by 2028.

M

Medtronic plc

Ireland

Follower1.5B

Offers Guardian Sensor 4 integrated with its MiniMed insulin pump systems, focusing on closed-loop automated insulin delivery solutions.

Ireland-headquartered medtech leader integrating CGM with its MiniMed insulin pump portfolio for automated closed-loop insulin delivery.

09

Recent Developments

25
2025Dexcom

Dexcom G7 receives expanded pediatric indication globally and secures coverage with all three major U.S. PBMs.

24
2024Abbott Laboratories

Abbott launches Lingo consumer CGM system targeting non-diabetic users for general health and wellness optimization.

10

Regulatory Landscape

FDA 510(k) clearance pathway for Class II continuous glucose monitoring devices in the United StatesEU MDR 2017/745 (Medical Device Regulation) compliance required for CGM market authorization in Europe
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

The CGM market offers high-growth potential, particularly in APAC and real-time CGM segments, with strong double-digit CAGR expected through 2032.

Operators

Focus on emerging market expansion, software integration, and next-gen sensor accuracy to capture growing demand for continuous glucose monitoring.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.